<DOC>
	<DOCNO>NCT01604850</DOCNO>
	<brief_summary>This study ass safety efficacy sofosbuvir combination ribavirin ( RBV ) administer 12 16 week participant genotypes 2 3 hepatitis C virus ( HCV ) infection assess proportion participant sustain virologic response ( SVR ) 12 week discontinuation therapy ( SVR12 ) .</brief_summary>
	<brief_title>Sofosbuvir + Ribavirin 12 16 Weeks Treatment Experienced Subjects With Chronic Genotype 2 3 HCV Infection ( FUSION )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Infection HCV genotype 2 3 Had cirrhosis determination Prior treatment failure Screening laboratory value within define threshold Subject treat investigational drug device within 30 day screen visit Use highly effective contraception method female childbearing potential sexually active male Prior exposure directacting antiviral target HCV nonstructural protein ( NS ) 5B polymerase Pregnant nursing female male pregnant female partner Current prior history clinical hepatic decompensation History clinically significant illness major medical disorder may interfere subject treatment , assessment compliance protocol Excessive alcohol ingestion significant drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>HCV genotype 2 ( GT-2 )</keyword>
	<keyword>HCV genotype 3 ( GT-3 )</keyword>
	<keyword>HCV</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>Treatment Experienced</keyword>
	<keyword>GS-7977</keyword>
	<keyword>Ribavirin</keyword>
</DOC>